- Aurion Biotech Appoints Edward J. Holland, M.D., as Chief Medical Officer and Eris P. Jordan, O.D., as Chief Development Officer
- Aurion Biotech Named to Fast Company’s Annual List of World’s Most Innovative Companies of 2025
- Aurion Biotech Announces Positive Topline Data for Phase 1/2 Clinical Trial of AURN001, an Allogeneic Cell Therapy Product Candidate for the Treatment of Corneal Edema Secondary to Corneal Endothelial Dysfunction
Millions of People Suffer from Sight-Threatening Corneal Endothelial Diseases
Our Cell Therapy Has the Potential to
Restore Their Vision
Company recognized for innovations in clinically validated cell therapy for corneal endothelial dystrophies
Get to know us.
We are a clinical-stage biotech company. We aim to restore vision to all who need it by developing a platform of innovative, accessible, and effective advanced therapies. Our first candidate is a patented cell therapy treatment for corneal endothelial disease.
Latest News
-
Aurion Biotech Appoints Edward J. Holland, M.D., as Chief Medical Officer and Eris P. Jordan, O.D., as Chief Development Officer
Read More -
Aurion Biotech Named to Fast Company’s Annual List of World’s Most Innovative Companies of 2025
Read More -
Aurion Biotech Announces Positive Topline Data for Phase 1/2 Clinical Trial of AURN001, an Allogeneic Cell Therapy Product Candidate for the Treatment of Corneal Edema Secondary to Corneal Endothelial Dysfunction
Read More